A. Periago

Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms

A. Minguela, V. Cabañas, J. A. Campillo, 2021, International journal of molecular sciences.

Circulating aberrant plasma cells allow risk stratification of patients with myeloma

A. Minguela, J. Moraleda, J. M. Bolarín, 2016, American journal of hematology.

Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.

A. Minguela, V. Cabañas, J. A. Campillo, 2021, American journal of cancer research.

Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.

A. Minguela, J. de la Rubia, V. Cabañas, 2021, American journal of cancer research.

Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing

A. Minguela, J. Moraleda, M. Álvarez-López, 2016, Oncoimmunology.

[Combined treatment with factor VIII and immunosuppressive agents in a young woman with acquired factor VIII inhibitor].

A. Periago, J. García-Talavera, M. José Aguado, 1996, Sangre.

Low‐affinity immunoglobulin gamma Fc region receptor III‐B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders

A. Minguela, E. Salido, J. A. Campillo, 2021, British Journal of Haematology.